Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
News|Articles|February 13, 2019
Tecentriq for Locally Advanced or Metastatic Urothelial Carcinoma
Author(s)Drew Boxler
Advertisement
Tecentriq (atezolizumab, Genetech)
Indications: Patients with locally advanced or metastatic urothelial carcinoma
- Not eligble for cisplatin-containing chemotherapy & whose tumors express PD-L1
- Not eligible for any platinum-containing chemotherapy regardless of PD-L1 status
- Have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy
Dosage
- Metastatic Urothelial Carcinoma or Previously Treated NSCLC
- 1200 mg intravenously 60 mins x 3weeks
- 1200 mg IV over 60 minutes, followed by bevacizumab, paclitaxel and carboplatin, on the same day every 3 weeks x4-6
Contraindications: none
Advertisement
Related to this article
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Advertisement
Advertisement
Trending on Drug Topics
1
American Pharmacists Month: PBM Reform, Provider Status Key in Stopping Pharmacy Deserts
2
Pfizer Reports Strong Phase 2 Data for 25-Valent Pediatric PCV
3
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
4
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
5